San Marcos, CA, United States of America

Yreka Ocampo

This inventor holds 1 USPTO granted patent and 2 EPO patents. Top assignee: Epigenomics Ag. Active years: 2015.


 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yreka Ocampo: Innovator in Prostate Cell Proliferative Disorders

Introduction

Yreka Ocampo is a notable inventor based in San Marcos, CA (US). He has made significant contributions to the field of gene expression analysis, particularly in relation to prostate cell proliferative disorders. His innovative work has led to the development of methods and nucleic acids that enhance the detection and differentiation of these disorders.

Latest Patents

Yreka Ocampo holds 1 patent for his invention titled "Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders." This patent provides methods and nucleic acids for the detection of and/or differentiation between prostate cell proliferative disorders. The invention focuses on analyzing the expression status of a panel of genes, or subsets thereof, to achieve accurate results.

Career Highlights

Ocampo is currently associated with Epigenomics AG, a company that specializes in molecular diagnostics. His work at Epigenomics AG has allowed him to further his research and contribute to advancements in the medical field, particularly in cancer diagnostics.

Collaborations

Yreka Ocampo has collaborated with notable colleagues such as Susan Cottrell and Su Yamamura. These collaborations have enriched his research and expanded the impact of his innovations in the field.

Conclusion

Yreka Ocampo's contributions to the analysis of gene expression in prostate cell proliferative disorders highlight his role as an important inventor in the medical research community. His innovative methods and dedication to advancing diagnostics continue to make a significant impact.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…